125 related articles for article (PubMed ID: 3927713)
1. Plasminogen-dependent fibrinolytic activity in normal human lymphocytes: diminished lymphocyte plasminogen activator in chronic lymphocytic leukemia.
Zucker S; Mehling K; Rai K
Am J Hematol; 1985 Aug; 19(4):373-86. PubMed ID: 3927713
[TBL] [Abstract][Full Text] [Related]
2. Adenylate cyclase in thymus-derived and bone marrow-derived lymphocytes from normal donors and patients with chronic lymphocytic leukemia.
Mendelsohn J; Nordberg J
J Clin Invest; 1979 Jun; 63(6):1124-32. PubMed ID: 221534
[TBL] [Abstract][Full Text] [Related]
3. The resistance of fibrin-stimulated tissue plasminogen activator to inactivation by a class PAI-2 inhibitor (minactivin).
Leung KC; Byatt JA; Stephens RW
Thromb Res; 1987 Jun; 46(6):755-66. PubMed ID: 2957818
[TBL] [Abstract][Full Text] [Related]
4. Fibrinolytic activity and species of plasminogen activator in human tears.
Hayashi K; Sueishi K
Exp Eye Res; 1988 Feb; 46(2):131-7. PubMed ID: 3127227
[TBL] [Abstract][Full Text] [Related]
5. [Interaction of plasminogen activator of urokinase type with human serum].
Vakulina OP; Popkova EV; Isachenkov VA
Vopr Med Khim; 1988; 34(4):32-6. PubMed ID: 3143185
[TBL] [Abstract][Full Text] [Related]
6. Aspirin effect on the release of plasminogen activator inhibitors by human platelets.
Woods AI; Lazzari MA
Thromb Res; 1988 Oct; 52(2):119-25. PubMed ID: 3143164
[TBL] [Abstract][Full Text] [Related]
7. [T-PA and PAI-1 in lymphocytes of patients with chronic lymphoid leukemia].
Kowalewska A; Rość D; Szadziewska-Kowalska D; Góralczyk K
Pol Arch Med Wewn; 2006 Mar; 115(3):197-202. PubMed ID: 18468424
[TBL] [Abstract][Full Text] [Related]
8. Depressed fibrinolysis in patients with acute leukaemia.
Guarini A; Mussoni L; Gugliotta L; Chetti L; Niewiarowski T; Catani L; Macchi S; Donati MB; Tura S
Br J Haematol; 1987 Jul; 66(3):327-30. PubMed ID: 2441734
[TBL] [Abstract][Full Text] [Related]
9. Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate.
Nielsen JD; Gram J; Fabrin K; Holm-Nielsen A; Jespersen J
Br J Urol; 1997 Jul; 80(1):105-10. PubMed ID: 9240188
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
Camiolo SM; Greco WR
Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
[TBL] [Abstract][Full Text] [Related]
11. Diurnal variation of the fibrinolytic system.
Grimaudo V; Hauert J; Bachmann F; Kruithof EK
Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085
[TBL] [Abstract][Full Text] [Related]
12. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
[TBL] [Abstract][Full Text] [Related]
13. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
14. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
[TBL] [Abstract][Full Text] [Related]
15. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.
Lucore CL; Fujii S; Sobel BE
Circulation; 1989 Jun; 79(6):1204-13. PubMed ID: 2498004
[TBL] [Abstract][Full Text] [Related]
16. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
Bachmann F
Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
[TBL] [Abstract][Full Text] [Related]
17. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
Lijnen HR; Dewerchin M; De Cock F; Collen D
Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
[TBL] [Abstract][Full Text] [Related]
18. Relationship between age and plasma t-PA, PA-inhibitor, and PA activity.
Hashimoto Y; Kobayashi A; Yamazaki N; Sugawara Y; Takada Y; Takada A
Thromb Res; 1987 Jun; 46(5):625-33. PubMed ID: 3114907
[TBL] [Abstract][Full Text] [Related]
19. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
Pannell R; Black J; Gurewich V
J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
[TBL] [Abstract][Full Text] [Related]
20. [Anti-activator inhibitors of plasminogen].
Juhan-Vague I; Alessi MC; Aillaud MF
Ann Biol Clin (Paris); 1987; 45(2):202-6. PubMed ID: 3113299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
